MOR MorphoSys AG

32.38
-0.02  -0%
Previous Close 32.4
Open 32.41
Price To Book 8.32
Market Cap 4,102,945,181
Shares 126,712,328
Volume 2,846
Short Ratio
Av. Daily Volume 90,724
Stock charts supplied by TradingView

NewsSee all news

  1. MorphoSys AG: Ad hoc: MorphoSys and Incyte Sign Global Collaboration and License Agreement, including U.S. Co-Commercialization and Ex-U.S. Commercialization Rights, for Tafasitamab

    PLANEGG/MUNICH, GERMANY / ACCESSWIRE / January 13, 2020 / MorphoSys AG ((FSE: MOR, Prime Standard Segment, MDAX &, TecDAX, NASDAQ:MOR) announces that it today has entered into a global collaboration and licensing

  2. MorphoSys and Incyte Sign Global Collaboration and License Agreement for Tafasitamab

    - MorphoSys and Incyte to co-commercialize tafasitamab in the U.S.- Incyte has exclusive commercialization rights outside of the U.S.- MorphoSys and Incyte to host joint conference call on January 13, 2020 at 7:00am PST

  3. MorphoSys Announces Submission of Biologics License Application for Tafasitamab in r/r DLBCL to the FDA

    PLANEGG/MUNICH, GERMANY / ACCESSWIRE / December 30, 2019 / MorphoSys AG ((FSE:MOR, Prime Standard Segment, MDAX &, TecDAX, NASDAQ:MOR) announced today that it has submitted a Biologics License Application (BLA) to the

  4. First Patient Dosed in Phase 1 Clinical Study of Tafasitamab in Firstline DLBCL

    PLANEGG/MUNICH, GERMANY / ACCESSWIRE / December 27, 2019 / MorphoSys AG ((FSE:MOR, Prime Standard Segment, MDAX &, TecDAX, NASDAQ:MOR) today announced that the first patient has been dosed in a phase 1b clinical study

  5. MorphoSys AG: Corporate Calendar 2020

    PLANEGG/MUNICH, GERMANY / ACCESSWIRE / December 12, 2019 / MorphoSys (NASDAQ:MOR) (FSE:MOR):Dear Madam/Sir,Please note MorphoSys's financial reporting dates 2020 as follows:For a direct import of the dates to your

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 ContRAst trial initiation announced July 3, 2019.
Otilimab (MOR103/GSK3196165)
Rheumatoid Arthritis
Phase 2 trial halted due to futility - October 28, 2019.
MOR106 IGUANA
Atopic dermatitis
Phase 2 data presented at ASH December 7, 2019.
MOR208 + idelalisib (COSMOS)
Chronic Lymphocytic Leukemia
Phase 3 futility analysis passed November 18, 2019. Top-line data due 1Q 2022.
Bendamustine + MOR208 - B-MIND
Relapsed or refractory diffuse large B cell lymphoma (r/r DLBCL)
BLA submission announced December 30, 2019.
Lenalidomide + MOR208 - L-MIND
Relapsed or refractory diffuse large B cell lymphoma
Phase 3 enrollment has commenced - noted June 14, 2018.
Gantenerumab
Early Alzheimer's disease
Phase 2/3 trial initiation announced July 11, 2018.
Guselkumab (GALAXI 1)
Crohn's disease
Phase 2 trial initiation announced November 19, 2018.
Guselkumab (NOVA)
Hidradenitis Suppurativa
Phase 3 primary endpoint met - December 12, 2018.
Guselkumab vs Cosentyx - ECLIPSE
Psoriasis
Phase 2a initiation announced January 17, 2019.
Guselkumab
Ulcerative colitis
Approval announced February 27, 2019.
Guselkumab
Plaque psoriasis
Phase 1b initiation of dosing announced December 27, 2019.
MOR208 tafasitamab
Front-line diffuse large B cell lymphoma (DLBCL)
Phase 1/2 trial to be initiated 4Q 2019.
MOR202
Membranous nephropathy
sBLA filing announced September 16, 2019.
Guselkumab
Psoriatic Arthritis
Phase 2b data due early 2020.
BPS-804 (setrusumab)
Osteogenesis Imperfecta

Latest News

  1. MorphoSys AG: Ad hoc: MorphoSys and Incyte Sign Global Collaboration and License Agreement, including U.S. Co-Commercialization and Ex-U.S. Commercialization Rights, for Tafasitamab

    PLANEGG/MUNICH, GERMANY / ACCESSWIRE / January 13, 2020 / MorphoSys AG ((FSE: MOR, Prime Standard Segment, MDAX &, TecDAX, NASDAQ:MOR) announces that it today has entered into a global collaboration and licensing

  2. MorphoSys and Incyte Sign Global Collaboration and License Agreement for Tafasitamab

    - MorphoSys and Incyte to co-commercialize tafasitamab in the U.S.- Incyte has exclusive commercialization rights outside of the U.S.- MorphoSys and Incyte to host joint conference call on January 13, 2020 at 7:00am PST

  3. MorphoSys Announces Submission of Biologics License Application for Tafasitamab in r/r DLBCL to the FDA

    PLANEGG/MUNICH, GERMANY / ACCESSWIRE / December 30, 2019 / MorphoSys AG ((FSE:MOR, Prime Standard Segment, MDAX &, TecDAX, NASDAQ:MOR) announced today that it has submitted a Biologics License Application (BLA) to the

  4. First Patient Dosed in Phase 1 Clinical Study of Tafasitamab in Firstline DLBCL

    PLANEGG/MUNICH, GERMANY / ACCESSWIRE / December 27, 2019 / MorphoSys AG ((FSE:MOR, Prime Standard Segment, MDAX &, TecDAX, NASDAQ:MOR) today announced that the first patient has been dosed in a phase 1b clinical study

  5. MorphoSys AG: Corporate Calendar 2020

    PLANEGG/MUNICH, GERMANY / ACCESSWIRE / December 12, 2019 / MorphoSys (NASDAQ:MOR) (FSE:MOR):Dear Madam/Sir,Please note MorphoSys's financial reporting dates 2020 as follows:For a direct import of the dates to your

  6. Markus Enzelberger, Chief Scientific Officer of MorphoSys, Announces His Departure

    PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 20, 2019 / MorphoSys AG ((FSE:MOR, Prime Standard Segment, MDAX &, TecDAX, NASDAQ:MOR) today announced that Dr. Markus Enzelberger, the company's Chief Scientific

  7. MorphoSys Continues to Build Commercial Presence by Opening new U.S. Headoffice

    PLANEGG/MUNICH, GERMANY and BOSTON MA / ACCESSWIRE / November 15, 2019 / MorphoSys ((FSE: MOR, Prime Standard Segment, MDAX &, TecDAX, NASDAQ:MOR) announced today the opening of its new U.S. headoffice. Based in

  8. Results for Bimagrumab in Obesity and Type 2 Diabetes Presented by MorphoSys's Partner

    PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 11, 2019 / MorphoSys AG ((FSE: MOR, Prime Standard Segment, MDAX &, TecDAX, NASDAQ:MOR) announced today that its licensee Novartis presented phase 2 results for

  9. MorphoSys to Present Data on Tafasitamab at ASH 2019 Meeting

    PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 6, 2019 / MorphoSys AG ((FSE:MOR, Prime Standard Segment, MDAX &, TecDAX, NASDAQ:MOR) today announced presentation of so far unpublished data on tafasitamab, its

  10. MOR106 clinical development in atopic dermatitis stopped for futility

    20.15 CET; regulated information - MorphoSys AG ((FSE: MOR, Prime Standard Segment, TecDAX, NASDAQ:MOR) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the end of the clinical development program of MOR106

  11. MOR106 clinical development in atopic dermatitis stopped for futility

    20.15 CET; regulated information - MorphoSys AG ((FSE: MOR, Prime Standard Segment, TecDAX, NASDAQ:MOR) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the end of the clinical development program of MOR106

  12. MOR106 clinical development in atopic dermatitis stopped for futility

    20.15 CET; regulated information - MorphoSys AG ((FSE: MOR, Prime Standard Segment, TecDAX, NASDAQ:MOR) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the end of the clinical development program of MOR106

  13. MOR106 clinical development in atopic dermatitis stopped for futility

    20.15 CET; regulated information - MorphoSys AG ((FSE: MOR, Prime Standard Segment, TecDAX, NASDAQ:MOR) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the end of the clinical development program of MOR106

  14. MOR106 clinical development in atopic dermatitis stopped for futility

    20.15 CET; regulated information - MorphoSys AG ((FSE: MOR, Prime Standard Segment, TecDAX, NASDAQ:MOR) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the end of the clinical development program of MOR106

  15. MOR106 clinical development in atopic dermatitis stopped for futility

    20.15 CET; regulated information - MorphoSys AG ((FSE: MOR, Prime Standard Segment, TecDAX, NASDAQ:MOR) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the end of the clinical development program of MOR106

  16. MOR106 clinical development in atopic dermatitis stopped for futility

    20.15 CET; regulated information - MorphoSys AG ((FSE: MOR, Prime Standard Segment, TecDAX, NASDAQ:MOR) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the end of the clinical development program of MOR106

  17. MOR106 clinical development in atopic dermatitis stopped for futility

    20.15 CET; regulated information - MorphoSys AG ((FSE: MOR, Prime Standard Segment, TecDAX, NASDAQ:MOR) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the end of the clinical development program of MOR106

  18. MorphoSys and I-Mab Biopharma Announce IND Clearance to Initiate Clinical Trials of MOR202/TJ202 for the Treatment of Multiple Myeloma in Mainland China

    PLANEGG/MUNICH, GERMANY and SHANGHAI, CHINA / ACCESSWIRE / October 14, 2019 / MorphoSys AG ((FSE:MOR, Prime Standard Segment, MDAX &, TecDAX, NASDAQ:MOR) and I-Mab Biopharma (I-Mab) announced today that I-Mab has

  19. I-Mab Biopharma and MorphoSys Announce IND Clearance to Initiate Clinical Trials of TJ202/MOR202 for the Treatment of Multiple Myeloma in Mainland China

    SHANGHAI, Oct. 14, 2019 /PRNewswire/ -- I-Mab Biopharma ("I-Mab"), a China and U.S.-based clinical stage biopharmaceutical company exclusively focused on the discovery and development of novel or highly

  20. MorphoSys to Present at Upcoming Investor Conferences

    PLANEGG/MUNICH, GERMANY / ACCESSWIRE / September 18, 2019 / MorphoSys AG ((FSE: MOR, Prime Standard Segment, MDAX &, TecDAX, NASDAQ:MOR) will present at the following conferences:Baader Investment ConferenceDate:

  21. MorphoSys's Licensee Janssen Submits Biologics License Application to U.S. FDA of Tremfya(R) (Guselkumab) for Treatment of Adults with Active Psoriatic Arthritis

    MorphoSys's Licensee Janssen Submits Biologics License Application to U.S. FDA of Tremfya(R) (Guselkumab) for Treatment of Adults with Active Psoriatic ArthritisPLANEGG / MUNICH, GERMANY / ACCESSWIRE / September